Venetoclax for CLL With Del(17p) Mutation: 6-Year Follow-Up and Subgroup Analyses
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia
Blood Adv 2024 Jan 30;[EPub Ahead of Print], S Stilgenbauer, E Tausch, AW Roberts, MS Davids, B Eichhorst, MJ Hallek, P Hilmen, C Schneider, J Schetelig, S Böttcher, AP Kater, Y Jiang, M Boyer, R Popovic, MT Ghanim, M Moran, WJ Sinai, X Wang, N Mukherjee, B Chyla, WG Wierda, JF SeymourFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.